Gilead Sciences, Inc.
GILD
$65.33
-$0.18-0.28%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -3.72% | 0.11% | 5.42% | -3.61% | 2.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.72% | 0.11% | 5.42% | -3.61% | 2.00% |
| Cost of Revenue | 15.40% | 12.19% | 0.00% | -1.62% | 1.38% |
| Gross Profit | -8.18% | -2.87% | 7.04% | -4.16% | 2.15% |
| SG&A Expenses | -47.77% | 8.41% | 36.26% | 21.79% | 22.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.85% | 16.31% | 20.23% | 13.47% | 14.12% |
| Operating Income | 25.91% | -18.10% | -19.08% | -25.15% | -16.58% |
| Income Before Tax | -18.56% | -4.69% | 5.66% | 955.26% | 167.59% |
| Income Tax Expenses | -40.45% | -77.40% | 49.18% | 292.68% | 3.92% |
| Earnings from Continuing Operations | -13.23% | 21.61% | -8.46% | 8,100.00% | 334.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 71.43% | 166.67% | -33.33% | 271.43% | 16.67% |
| Net Income | -12.87% | 21.86% | -8.65% | 5,215.79% | 329.32% |
| EBIT | 25.91% | -18.10% | -19.08% | -25.15% | -16.58% |
| EBITDA | 26.71% | -11.48% | -10.19% | -17.97% | -14.17% |
| EPS Basic | -12.59% | 22.54% | -8.14% | 5,259.60% | 330.75% |
| Normalized Basic EPS | 29.91% | -16.24% | -17.11% | -21.92% | -15.29% |
| EPS Diluted | -13.13% | 21.83% | -8.79% | 5,198.01% | 333.27% |
| Normalized Diluted EPS | 30.31% | -16.44% | -17.44% | -22.30% | -15.70% |
| Average Basic Shares Outstanding | -0.32% | -0.56% | -0.56% | -0.56% | -0.32% |
| Average Diluted Shares Outstanding | -0.63% | -0.32% | -0.16% | -0.08% | 0.16% |
| Dividend Per Share | 2.74% | 2.74% | 2.74% | 2.74% | 2.82% |
| Payout Ratio | 0.18% | -0.16% | 0.12% | -0.98% | -0.76% |
